Skip to content
Men Under Microscope – Lifestyle
Author:
First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
October 11, 2026
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
May 21, 2026
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
April 20, 2026